Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

OncoSolid™ Peritoneal Metastatic Colorectal Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Peritoneal Metastatic Colorectal Cancer Organoid Models

Peritoneal metastatic (PM) colorectal cancer is an advanced malignant that makes up 10% of colorectal cancer. Though surgery resection and chemotherapies are functional clinical options, the poor survival and high recurrence rate of cancer demonstrate the strong demand for developing more effective clinical approaches. Organoid is a valuable in vitro tumor culture that recapitulates the molecular and phenotypic features of individual-patient tumor tissue and plays a key role in tumor profiling and promising therapy development.

Peritoneal Metastatic Colorectal Cancer Organoid Models at Creative Biolabs

Creative Biolabs is a lead service provider in immunotherapy, and now we present preclinical cancer organoid models and their use for efficacy tests of the modified immune cell products.

Workflow

Fig.1 Working step of Peritoneal metastatic colorectal cancer organoid generation and use for evaluation. (Ubink, et al., 2019)

Various Sources of Tumor Tissue

Complete Cancer Organoid Characterization System

Using cut-in-edge biological techniques and methods, we perform a thorough characterization of organoids and initial tumor tissue to profile the features of the organoid model for the following application.

CAR-T Efficacy Test Using Cancer Organoids

The organoid model is of clinical relevance since the organoid response is correlated to cancer patients and hence can be used to predict patients' responses.

Application of Peritoneal Metastatic Colorectal Cancer Organoids

Key Features

• Cancer organoid models recapitulate the heterogenous of patients and tumor tissues
• Establish an organoid platform for cancer study and treatment development
• Highly relevant pre-clinical PM models
• Enough organoid cultures allow various characterizations

Related CAR-T Products at Creative Biolabs

As the leading biotech in the immunotherapy field, we provide multiple products for chimeric antigen receptor (CAR) T cell construction and lateral in vitro cytotoxicity tests. Our products include CAR vectors, viral particles, immune cell products, and so on. Moreover, we offer customized CAR-T, CAR-MA, CAR-NK, and TCR-T therapy development services.

Organoid is the most clinically relevant in vitro model for many healthy tissues and cancer with the advantage of easy manipulation. We offer a living biobank of cancer organoid models for CAR-T therapy development for complicated solid tumors. Please contact us and learn more about the services.

References

1. Ubink, I.; et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy. The British journal of surgery. 2019, 106 (10): 1404-1414.
2. Giuliano, S.; Pagès, G. Mechanisms of resistance to anti-angiogenesis therapies. Biochimie. 2019, 95 6: 1110-9.
3. Kranenburg, O.; et al. Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges. Frontiers in oncology. 2021, 11: 650098.
4. Baaten, I. C. P. A.; et al. Colorectal cancer peritoneal metastases: Biology, treatment and next steps. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2020, 46(4 Pt A): 675-683.